Cargando…
Successful Prevention of Fetal Autoimmune-Mediated Heart Block by Combined Therapies With Hydroxychloroquine and Intravenous Immunoglobulin: A Case Report
A fetal autoimmune-mediated atrioventricular block is a passively acquired autoimmune disease in which maternal autoantibodies enter the fetal circulation via the placenta and subsequently cause inflammation and fibrosis of the atrioventricular node. Once fetal autoimmune-mediated atrioventricular b...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8636095/ https://www.ncbi.nlm.nih.gov/pubmed/34869674 http://dx.doi.org/10.3389/fcvm.2021.759260 |
_version_ | 1784608464643817472 |
---|---|
author | Zhao, Li Zhou, Yan Wang, Chuan Li, Yifei Zhu, Qi Hua, Yimin Qiao, Lina Wu, Jinlin Zhou, Kaiyu |
author_facet | Zhao, Li Zhou, Yan Wang, Chuan Li, Yifei Zhu, Qi Hua, Yimin Qiao, Lina Wu, Jinlin Zhou, Kaiyu |
author_sort | Zhao, Li |
collection | PubMed |
description | A fetal autoimmune-mediated atrioventricular block is a passively acquired autoimmune disease in which maternal autoantibodies enter the fetal circulation via the placenta and subsequently cause inflammation and fibrosis of the atrioventricular node. Once fetal autoimmune-mediated atrioventricular block occurs, it only takes a short time to progress from first-degree atrioventricular block to complete atrioventricular block, meaning that the damage is often irreversible. Autoimmune—associated AVB, a rare but life—threatening disorder, occurs in 2–5% of pregnancies with positive anti—Ro/SSA (the most common one) and La/SSB antibodies. The perinatal mortality of neonates with AVB outlined in research is approximately 30%. Thus far, for autoimmune-associated AVB fetuses, currently used treatments include corticosteroids, hydroxychloroquine, intravenous immunoglobulin (IVIG), b—sympathomimetic agent, and even plasma exchange. Currently, approaches for preventing the progression and recurrence of a fetal atrioventricular block are still controversial. Here, we reported a baby of successful prevention from the fate of the fetal atrioventricular block by adopting prophylactic comprehensive prenatal therapy. |
format | Online Article Text |
id | pubmed-8636095 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-86360952021-12-02 Successful Prevention of Fetal Autoimmune-Mediated Heart Block by Combined Therapies With Hydroxychloroquine and Intravenous Immunoglobulin: A Case Report Zhao, Li Zhou, Yan Wang, Chuan Li, Yifei Zhu, Qi Hua, Yimin Qiao, Lina Wu, Jinlin Zhou, Kaiyu Front Cardiovasc Med Cardiovascular Medicine A fetal autoimmune-mediated atrioventricular block is a passively acquired autoimmune disease in which maternal autoantibodies enter the fetal circulation via the placenta and subsequently cause inflammation and fibrosis of the atrioventricular node. Once fetal autoimmune-mediated atrioventricular block occurs, it only takes a short time to progress from first-degree atrioventricular block to complete atrioventricular block, meaning that the damage is often irreversible. Autoimmune—associated AVB, a rare but life—threatening disorder, occurs in 2–5% of pregnancies with positive anti—Ro/SSA (the most common one) and La/SSB antibodies. The perinatal mortality of neonates with AVB outlined in research is approximately 30%. Thus far, for autoimmune-associated AVB fetuses, currently used treatments include corticosteroids, hydroxychloroquine, intravenous immunoglobulin (IVIG), b—sympathomimetic agent, and even plasma exchange. Currently, approaches for preventing the progression and recurrence of a fetal atrioventricular block are still controversial. Here, we reported a baby of successful prevention from the fate of the fetal atrioventricular block by adopting prophylactic comprehensive prenatal therapy. Frontiers Media S.A. 2021-11-12 /pmc/articles/PMC8636095/ /pubmed/34869674 http://dx.doi.org/10.3389/fcvm.2021.759260 Text en Copyright © 2021 Zhao, Zhou, Wang, Li, Zhu, Hua, Qiao, Wu and Zhou. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cardiovascular Medicine Zhao, Li Zhou, Yan Wang, Chuan Li, Yifei Zhu, Qi Hua, Yimin Qiao, Lina Wu, Jinlin Zhou, Kaiyu Successful Prevention of Fetal Autoimmune-Mediated Heart Block by Combined Therapies With Hydroxychloroquine and Intravenous Immunoglobulin: A Case Report |
title | Successful Prevention of Fetal Autoimmune-Mediated Heart Block by Combined Therapies With Hydroxychloroquine and Intravenous Immunoglobulin: A Case Report |
title_full | Successful Prevention of Fetal Autoimmune-Mediated Heart Block by Combined Therapies With Hydroxychloroquine and Intravenous Immunoglobulin: A Case Report |
title_fullStr | Successful Prevention of Fetal Autoimmune-Mediated Heart Block by Combined Therapies With Hydroxychloroquine and Intravenous Immunoglobulin: A Case Report |
title_full_unstemmed | Successful Prevention of Fetal Autoimmune-Mediated Heart Block by Combined Therapies With Hydroxychloroquine and Intravenous Immunoglobulin: A Case Report |
title_short | Successful Prevention of Fetal Autoimmune-Mediated Heart Block by Combined Therapies With Hydroxychloroquine and Intravenous Immunoglobulin: A Case Report |
title_sort | successful prevention of fetal autoimmune-mediated heart block by combined therapies with hydroxychloroquine and intravenous immunoglobulin: a case report |
topic | Cardiovascular Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8636095/ https://www.ncbi.nlm.nih.gov/pubmed/34869674 http://dx.doi.org/10.3389/fcvm.2021.759260 |
work_keys_str_mv | AT zhaoli successfulpreventionoffetalautoimmunemediatedheartblockbycombinedtherapieswithhydroxychloroquineandintravenousimmunoglobulinacasereport AT zhouyan successfulpreventionoffetalautoimmunemediatedheartblockbycombinedtherapieswithhydroxychloroquineandintravenousimmunoglobulinacasereport AT wangchuan successfulpreventionoffetalautoimmunemediatedheartblockbycombinedtherapieswithhydroxychloroquineandintravenousimmunoglobulinacasereport AT liyifei successfulpreventionoffetalautoimmunemediatedheartblockbycombinedtherapieswithhydroxychloroquineandintravenousimmunoglobulinacasereport AT zhuqi successfulpreventionoffetalautoimmunemediatedheartblockbycombinedtherapieswithhydroxychloroquineandintravenousimmunoglobulinacasereport AT huayimin successfulpreventionoffetalautoimmunemediatedheartblockbycombinedtherapieswithhydroxychloroquineandintravenousimmunoglobulinacasereport AT qiaolina successfulpreventionoffetalautoimmunemediatedheartblockbycombinedtherapieswithhydroxychloroquineandintravenousimmunoglobulinacasereport AT wujinlin successfulpreventionoffetalautoimmunemediatedheartblockbycombinedtherapieswithhydroxychloroquineandintravenousimmunoglobulinacasereport AT zhoukaiyu successfulpreventionoffetalautoimmunemediatedheartblockbycombinedtherapieswithhydroxychloroquineandintravenousimmunoglobulinacasereport |